secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0000875320-22-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B
------------------------------------------------------------------------------

- Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.
- GAAP diluted EPS $3.59; non-GAAP diluted EPS $4.01, up 14% YoY.
- Full-year 2022 product revenue guidance raised to $8.8-8.9B from prior $8.6-8.7B.
- Initiating global regulatory submissions for exa-cel (sickle cell/beta thalassemia) in 2022; Phase 3 for VX-548 (acute pain) started.
- Cash and marketable securities $11.5B as of Sept 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000036/0000875320-22-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532022000036/vrtx-20221027.htm
  HTML page:      https://secwatch.observer/filing/0000875320-22-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer